Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HydroVax-001 Phase 1 in Healthy Adults
NCT02337868Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2015
- Primary completion
- Dec 2016
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HydroVax-001 in West Nile virus infection (WNV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Occurrence of any AE related to the study vaccine, Occurrence of Grade 3 laboratory toxicities related to the study vaccine and 3 more. Started Mar 2015; status: completed.
02
Drugs
HydroVax-001
03
Conditions
West Nile virus infection (WNV)
Beyond the preview
Go deeper on NCT02337868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337868.